Skip to main content
. 2019 Aug 27;30(10):1622–1629. doi: 10.1093/annonc/mdz287

Table 2.

Univariate and multivariable disease-free survival Cox models (stratified by sex, gene expression profiling platform and adjuvant chemotherapy status)

Disease-free survival Cox models (all patients) (N =2 636 769 events)
  Univariate analysis
Multivariable analysis
  HR 95% CI P value HR 95% CI P value
Age 1.01 1–1.02 <0.001 1.01 1–1.02 <0.001
pT2/pT1 versus pT3 1.07 0.65–1.75 0.8 0.86 0.52–1.43 0.56
pT4 versus pT3 1.37 1.11–1.69 0.003 1.46 1.18–1.81 <0.001
pN1 versus pN0 1.99 1.61–2.46 <0.001 2.05 1.65–2.55 <0.001
pN2 versus pN0 3.08 2.41–3.93 <0.001 3.15 2.45–4.05 <0.001
Rectum versus left 1.03 0.76–1.40 0.83 0.94 0.69–1.29 0.72
Right versus left 0.84 0.72–0.97 0.02 0.86 0.73–1.00 0.05
MSI versus MSS 0.76 0.61 –0.93 0.008 0.88 0.7–1.11 0.29
KRAS mut versus wild-type 1.04 0.9–1.21 0.55
BRAF mut versus wild-type 0.9 0.72 − 1.13 0.35
CMS4 score 1.37 1.07–1.76 0.01 0.93 0.64–1.32 0.67
CAF infiltration score 1.6 0.93–2.74 0.09 2.54 1.08–6.02 0.03
CytoLym infiltration score 0.45 0.25–0.78 0.005 0.26 0.12–0.55 <0.001

CAF, cancer-associated fibroblast; CytoLym, cytotoxic lymphocytes. P values ≤0.05 displayed in bold.